What drug class does Cabozantinib belong to?

Cabozantinib (Cabozantinib) is a small molecule multi-target tyrosine kinase inhibitor that occupies an important position in the field of anti-tumor targeted therapy. From the perspective of drug category, it is not a single target inhibitor, but acts simultaneously on multiple signaling pathways closely related to tumor growth, angiogenesis and metastasis. This is also an important reason why it has been widely studied and applied in a variety of solid tumors. Overseas research generally believes that cabozantinib can block the proliferation signals of tumor cells to a certain extent by inhibiting various receptor tyrosine kinases such as VEGFR, MET, and AXL, and at the same time weaken the environment for the formation of new blood vessels in tumors, thereby achieving the purpose of controlling disease progression.

In terms of clinical application, cabozantinib is mainly used for diseases such as renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer, and pancreatic neuroendocrine tumors. These tumors are often closely related to abnormal angiogenesis and signaling pathway activation, and the multi-target properties of cabozantinib make it more therapeutic potential in complex tumor environments. Unlike traditional chemotherapy drugs, cabozantinib does not directly kill rapidly dividing cells, but interferes with tumor development by "precisely blocking signals", so it is usually classified as a targeted anti-cancer drug.

Based on medication experience, cabozantinib is often used in patients who have received other systemic treatments in the past, or as one of the important options in specific treatment stages. Its pharmacological characteristics determine that the drug needs to be taken long-term and regularly during treatment to maintain continued inhibition of relevant signaling pathways. At the same time, due to the existence of multi-target mechanisms of action, patients also need to pay attention to changes in blood pressure, liver function, skin reactions, gastrointestinal reactions, etc. during medication, and make adjustments under the guidance of a doctor. Overall, cabozantinib represents the development trend of modern targeted therapy from"single point attack" to "multi-pathway intervention", and has clear drug positioning and research value in a variety of refractory solid tumors.

Keyword tags: Cabozantinib drug category,Cabozantinib targeted drug, multi-target tyrosine kinase inhibitor, renal cell carcinoma drug, hepatocellular carcinoma targeted therapy, thyroid cancer drug, neuroendocrine tumor treatment

Reference:https://en.wikipedia.org/wiki/Cabozantinib